Nidhi Kochar

发表

10 A Review of Statistical Analyses for Competing Risks

Melvin L. Moeschberger, Kevin P. Tordoff, M. Moeschberger, 2007 .

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial

Shuying S Li, M. McElrath, J. McElrath, 2018, PloS one.

Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.

Allan C. deCamp, J. Mullins, J. Kublin, 2021, The New England journal of medicine.

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

Allan C. deCamp, J. Kublin, J. Mascola, 2017, Statistical communications in infectious diseases.

Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody

Allan C. deCamp, J. Mascola, P. Gilbert, 2021, Journal of acquired immune deficiency syndromes.

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)

J. Fuchs, S. Kalams, N. Frahm, 2015, Open forum infectious diseases.

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

Lindsay N. Carpp, Allan C. deCamp, J. Mullins, 2022, Nature Medicine.

Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects.

W. Blattner, M. McElrath, N. Russell, 2011, The Journal of infectious diseases.

Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.

H. Liao, B. Haynes, J. Fuchs, 2015, Journal of AIDS & clinical research.

A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings

J. Mascola, J. Ledgerwood, L. Corey, 2021, Journal of acquired immune deficiency syndromes.

HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.

H. Liao, B. Haynes, D. Montefiori, 2014, The Journal of clinical investigation.

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA

R. Gottardo, N. Frahm, Greg Finak, 2017, Clinical and Vaccine Immunology.

Phase Angle of Entrainment in Morning‐ and Evening‐Types under Naturalistic Conditions

J. Emens, A. Lewy, Nidhi Kochar, 2009, Chronobiology international.